ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Evaluation of the Impact of Universal Mupirocin Decolonization in Intensive Care Units on the Utility of Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Swab Testing.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe reliability of methicillin-resistant Staphylococcus aureus (MRSA) polymerase chain reaction (PCR) nasal swab testing in the context of mupirocin nasal decolonization has been questioned. This study investigated whether the negative predictive value (NPV) of MRSA PCR nasal swab testing following mupirocin decolonization was noninferior to testing prior to decolonization.
methodsThis retrospective cohort study included adult inpatients admitted to intensive care units (ICUs) from February 2023 to August 2024 who underwent both MRSA PCR nasal swab testing and universal mupirocin decolonization. Patients were divided into 3 groups based on timing of PCR testing: prior to receiving any doses of topical mupirocin, no more than 7 days after, or >7 days after a first dose. The primary outcome was the NPV of MRSA PCR nasal swab testing.
resultsA total of 1034 patients were included in the primary analysis; 508 (49.1%) had a MRSA PCR nasal swab collected prior to the start of decolonization and 388 (73.8%) and 138 (26.2%) received nasal swabs > 0 to ≤7 days and >7 days after the start of mupirocin decolonization, respectively. The differences between the NPV of MRSA PCR testing in patients with swabs collected prior versus in patients with swabs collected >0 to ≤7 days and >7 days after the start of mupirocin were 0.3% and -0.4% (1-sided 95% CI -.9% and CI -2.3%), respectively.
conclusionsThe NPV of MRSA PCR nasal swabs is not diminished after mupirocin decolonization. MRSA PCR testing within 7 days of initiation of decolonization is noninferior to testing prior to decolonization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.